3 ms·
The article doesn't give details, but one of the quoted authors has participated in trials testing anti-ICOS antibody alone or in combination with atezolizumab,
by ma2t 4y ago
The article doesn't give details, but one of the quoted authors has participated in trials testing anti-ICOS antibody alone or in combination with atezolizumab, with results presented at an ASCO meeting: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.2624 https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.26...
Describes one complete response in TNBC (and 4 partial responses in TNBC and other cancers). Couldn't find a related peer-reviewed journal article on very quick search.
- adamredwoods 4y agoI have not heard of anti-ICOS (Inducible costimulatory receptor) before. Seems specific to TME. KY1044 with mouse models (different authors): https://aacrjournals.org/cancerimmunolres/article/8/12/1568/469583/An-Antibody-Targeting-ICOS-Increases-Intratumoral https://aacrjournals.org/cancerimmunolres/article/8/12/1568/... KY1044 I think is Kymab in Cambridge: https://www.kymab.com/pipeline/ky1044/ https://www.kymab.com/pipeline/ky1044/
- ma2t 4y agoYes, Sanofi licensed from Kymab. There are a few groups targeting ICOS/ICOSL to modulate immune response to tumor (either alone or in combo with PD-1, CTLA-4, etc approaches previously mentioned on HN). Here's one reasonably recent backgrounder on rationale: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003380/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003380/ Still not clear that KY1044 really is the "experimental drug" mentioned in the linked BBC article, since as others have noted the article is pretty thin on detail.